Genus plc: Hold Rating Amid Regulatory Uncertainties and Market Dependencies

Christian Glennie, an analyst from Stifel Nicolaus, maintained the Hold rating on Genus plc (GNS – Research Report). The associated price target is p1,850.00.

Christian Glennie has given his Hold rating due to a combination of factors related to Genus plc’s recent developments and market conditions. The company has achieved a significant milestone by obtaining FDA approval for its PRP gene-edited pigs, which is expected to positively impact its market position. However, the successful commercialization in the US market is contingent upon securing further approvals in key export markets like Mexico, Canada, and Japan, where the timing of approvals remains uncertain.
Additionally, while the FDA approval is a positive step, there are concerns regarding the harmonization of trade between the US and these countries, especially given current tariff uncertainties. Although there is potential for modest PRP revenues starting in 2026 and significant sales by 2032, the lack of clarity on regulatory pathways and consumer labeling requirements in the US adds to the cautious outlook. Therefore, while the company shows promise, the uncertainties and dependencies on external approvals and market conditions justify a Hold rating.

According to TipRanks, Glennie is ranked #8730 out of 9371 analysts.